Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.24
(-5.4%)
USD 1.24
(-5.4%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.07 Million USD | 55.28% |
| 2022 | 2.25 Million USD | -22.11% |
| 2021 | 2.89 Million USD | -79.55% |
| 2020 | 14.15 Million USD | 236.42% |
| 2019 | 4.2 Million USD | -86.01% |
| 2018 | 30.05 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.36 Million USD | -31.87% |
| 2024 Q1 | 3.47 Million USD | -0.74% |
| 2023 Q2 | 2.36 Million USD | -8.24% |
| 2023 Q1 | 2.57 Million USD | 14.15% |
| 2023 FY | 3.5 Million USD | 55.28% |
| 2023 Q4 | 3.5 Million USD | 63.25% |
| 2023 Q3 | 2.14 Million USD | -9.19% |
| 2022 Q2 | 2.56 Million USD | -6.22% |
| 2022 Q1 | 2.73 Million USD | -5.63% |
| 2022 Q3 | 2.38 Million USD | -6.95% |
| 2022 FY | 2.25 Million USD | -22.11% |
| 2022 Q4 | 2.25 Million USD | -5.41% |
| 2021 FY | 2.89 Million USD | -79.55% |
| 2021 Q2 | 13.93 Million USD | -0.78% |
| 2021 Q1 | 14.04 Million USD | 3.69% |
| 2021 Q4 | 2.89 Million USD | -5.18% |
| 2021 Q3 | 3.05 Million USD | -78.1% |
| 2020 Q2 | 13.82 Million USD | -1.08% |
| 2020 FY | 14.15 Million USD | 236.42% |
| 2020 Q4 | 13.54 Million USD | -0.86% |
| 2020 Q3 | 13.66 Million USD | -1.16% |
| 2020 Q1 | 13.97 Million USD | 291.62% |
| 2019 Q4 | 3.56 Million USD | -89.43% |
| 2019 Q3 | 33.77 Million USD | -3.2% |
| 2019 Q2 | 34.89 Million USD | 5.51% |
| 2019 Q1 | 33.07 Million USD | 10.55% |
| 2019 FY | 4.2 Million USD | -86.01% |
| 2018 Q4 | 29.91 Million USD | 0.0% |
| 2018 FY | 30.05 Million USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| uniQure N.V. | 138.4 Million USD | 97.779% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 94.606% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 99.309% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 94.688% |
| bluebird bio, Inc. | 330.32 Million USD | 99.069% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 92.879% |
| Imunon, Inc. | 1.13 Million USD | -169.816% |
| Editas Medicine, Inc. | 36.53 Million USD | 91.586% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.978% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.858% |
| Myriad Genetics, Inc. | 145 Million USD | 97.88% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.282% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 92.598% |
| Verastem, Inc. | 41.55 Million USD | 92.603% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.968% |
| Waters Corporation | 2.35 Billion USD | 99.869% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.991% |
| Biogen Inc. | 7.33 Billion USD | 99.958% |
| Nektar Therapeutics | 230.4 Million USD | 98.666% |
| Perrigo Company plc | 4.07 Billion USD | 99.925% |
| Dynavax Technologies Corporation | 256.91 Million USD | 98.803% |
| Illumina, Inc. | 2.26 Billion USD | 99.864% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 85.281% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -207.4% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 98.231% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 88.611% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.729% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 91.933% |
| Evolus, Inc. | 126.54 Million USD | 97.571% |
| Adicet Bio, Inc. | 17.7 Million USD | 82.636% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.886% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.432% |
| FibroGen, Inc. | 170.45 Million USD | 98.197% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.888% |
| OPKO Health, Inc. | 326.56 Million USD | 99.059% |
| Homology Medicines, Inc. | 44.05 Million USD | 93.022% |
| Geron Corporation | 85.89 Million USD | 96.421% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.872% |
| Exelixis, Inc. | 189.94 Million USD | 98.382% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -143.968% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 97.335% |
| Zoetis Inc. | 6.8 Billion USD | 99.955% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 98.351% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 30.168% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.62% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 91.537% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.789% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.78% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -1935.762% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.795% |
| Blueprint Medicines Corporation | 774.12 Million USD | 99.603% |
| Insmed Incorporated | 1.2 Billion USD | 99.745% |
| TG Therapeutics, Inc. | 110.79 Million USD | 97.226% |
| Incyte Corporation | 38.28 Million USD | 91.971% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 99.65% |